Possible use of Trichuris suis ova in autism spectrum disorders therapy

Medical Hypotheses

Volumn 81, Issue 1, 2013, Pages 1-4

  Siniscalco, Dario ^a,b,c   Antonucci, Nicola ^d  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Centre for Autism   (Italy)

^c Cancellautismo no profit association for autism care   (Italy)

^d Biomedical Centre for Autism Research and Treatment   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CARNITINE; GLUTAMATE RECEPTOR ANTAGONIST; MELATONIN; NALTREXONE; OXYTOCIN; PROBIOTIC AGENT;

ARTICLE; AUTISM; DIET SUPPLEMENTATION; HUMAN; HYPERBARIC OXYGEN; IMMUNOMODULATION; TRICHURIS SUIS;

ANIMALS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; MODELS, THEORETICAL; TRICHURIS;

TRICHURIS SUIS; VERMES;

EID: 84878527894     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.03.024     Document Type: Article

References (69)

1. Siniscalco D., Bradstreet J.J., Antonucci N. The promise of regenerative medicine and stem cell research for the treatment of autism. J Regen Med 2012, 1:1.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, text revision. 4th ed. Washington, DC; 2000.
3. Stanković M., Lakić A., Ilić N. Autism and autistic spectrum disorders in the context of new DSM-V classification, and clinical and epidemiological data. Srp Arh Celok Lek 2012, 140(3-4):236-243.
4. Toro R., Konyukh M., Delorme R., et al. Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet 2010, 26:363-372.
5. Herbert M.R. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Curr Opin Neurol 2010, 23:103-110.
6. Siniscalco D., Sapone A., Cirillo A., Giordano C., Maione S., Antonucci N. Autism spectrum disorders: is mesenchymal stem cell personalized therapy the future?. J Biomed Biotechnol 2012, 2012:480289.
7. Karst J.S., Van Hecke A.V. Parent and family impact of autism spectrum disorders: a review and proposed model for intervention evaluation. Clin Child Fam Psychol Rev 2012, 15(3):247-277.
8. Baio J. Prevalence of autism spectrum disorders - autism and developmental disabilities monitoring network, 14 Sites, United States, 2008. CDC Surveill Summ. 2012;61(SS03):1-19.
9. Chadman K.K., Guariglia S.R., Yoo J.H. New directions in the treatment of autism spectrum disorders from animal model research. Expert Opin Drug Disc 2012, 7(5):407-416.
10. Hampson D.R., Gholizadeh S., Pacey L.K. Pathways to drug development for autism spectrum disorders. Clin Pharmacol Ther 2012, 91(2):189-200.
11. Rosen L.D., Bailey M.L., Becker D., et al. Sensory integration therapies for children with developmental and behavioral disorders. Pediatrics 2012, 129(6):1186-1189.
12. Nevels R.M., Dehon E.E., Alexander K., Gontkovsky S.T. Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Exp Clin Psychopharmacol 2010, 18:184-201.
13. McCracken J.T. Safety issues with drug therapies for autism spectrum disorders. J Clin Psychiatry 2005, 66:32-37.
14. Tandon M., Pruett J.R. An overview of the use of antidepressants in children and adolescents. Mol Med 2008, 105:79-84.
15. Doyle C.A., McDougle C.J. Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opin Pharmacother 2012, 13(11):1615-1629.
16. Rossignol D.A. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiatry 2009, 21(4):213-236.
17. Senel H.G. Parents' views and experiences about complementary and alternative medicine treatments for their children with autistic spectrum disorder. J Autism Dev Disord 2010, 40:494-503.
18. Wong V.C., Sun J.G. Randomized controlled trial of acupuncture versus sham acupuncture in autism spectrum disorder. J Altern Complement Med 2010, 16:545-553.
19. Filipek P.A., Steinberg-Epstein R., Book T.M. Intervention for autistic spectrum disorders. NeuroRx 2006, 3:207-216.
20. LeBlanc L.A., Gillis J.M. Behavioral interventions for children with autism spectrum disorders. Pediatr Clin North Am 2012, 59(1):147-164.
21. Vismara L.A., Rogers S.J. Behavioral treatments in autism spectrum disorder: what do we know?. Annu Rev Clin Psychol 2010, 6:447-468.
22. Kasari C., Lawton K. New directions in behavioral treatment of autism spectrum disorders. Curr Opin Neurol 2010, 23:137-143.
23. Ramdoss S., Machalicek W., Rispoli M., Mulloy A., Lang R., O'Reilly M. Computer-based interventions to improve social and emotional skills in individuals with autism spectrum disorders: a systematic review. Dev Neurorehabil 2012, 15(2):119-135.
24. Castro GA. In: Baron S, editor. Helminths: structure, classification, growth, and development. Medical microbiology. 4th ed. Galveston (TX): University of Texas Medical Branch at Galveston; 1996.
25. Elliott D.E., Weinstock J.V. Helminthic therapy: using worms to treat immune-mediated disease. Adv Exp Med Biol 2009, 666:157-166.
26. Jouvin M.H., Kinet J.P. Trichuris suis ova: testing a helminth-based therapy as an extension of the hygiene hypothesis. J Allergy Clin Immunol 2012, 130(1):3-10.
27. Ben-Ami Shor D, Harel M, Eliakim R, Shoenfeld Y. The Hygiene theory harnessing helminths and their ova to treat autoimmunity. Clin Rev Allergy Immunol, in press. http://dx.doi.org/10.1007/s12016-012-8352-9.
28. Fleming J.O. Helminth therapy and multiple sclerosis. Int J Parasitol 2013, 43(3-4):259-274.
29. Croft A.M., Bager P., Kumar S. Helminth therapy (worms) for allergic rhinitis. Cochrane Database Syst Rev 2012, 4:CD009238.
30. Adisakwattana P., Saunders S.P., Nel H.J., Fallon P.G. Helminth-derived immunomodulatory molecules. Adv Exp Med Biol 2009, 666:95-107.
31. McKay D.M. The therapeutic helminth?. Trends Parasitol 2009, 25(3):109-114.
32. Erb K.J. Can helminths or helminth-derived products be used in humans to prevent or treat allergic diseases?. Trends Immunol 2009, 30(2):75-82.
33. Soares M.F., Araújo C.A. Helminth products as a potential therapeutic strategy for inflammatory diseases. Inflamm Allergy Drug Targets 2008, 7(2):113-118.
34. Harnett W., Harnett M.M. Therapeutic immunomodulators from nematode parasites. Expert Rev Mol Med 2008, 10:e18.
35. Harnett W., Harnett M.M. Helminth-derived immunomodulators: can understanding the worm produce the pill?. Nat Rev Immunol 2010, 10(4):278-284.
36. Yamamoto-Furusho J.K. Innovative therapeutics for inflammatory bowel disease. World J Gastroenterol 2007, 13(13):1893-1896.
37. Croese J., O'Neil J., Masson J., et al. A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors. Gut 2006, 55:136-137.
38. Bourke C.D., Mutapi F., Nausch N., et al. Trichuris suis ova therapy for allergic rhinitis does not affect allergen-specific cytokine responses despite a parasite-specific cytokine response. Clin Exp Allergy 2012, 42(11):1582-1595.
39. Fleming J.O., Isaak A., Lee J.E., et al. Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study. Mult Scler 2011, 17(6):743-754.
40. Summers R.W., Elliott D.E., Urban J.F., Thompson R.A., Weinstock J.V. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005, 128(4):825-832.
41. Garud S., Peppercorn M.A. Ulcerative colitis: current treatment strategies and future prospects. Ther Adv Gastroenterol 2009, 2(2):99-108.
42. Summers R.W., Elliott D.E., Urban J.F., Thompson R., Weinstock J.V. Trichuris suis therapy in Crohn's disease. Gut 2005, 54(1):87-90.
43. Summers R.W., Elliott D.E., Qadir K., Urban J.F., Thompson R., Weinstock J.V. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 2003, 98(9):2034-2041.
44. Hunter M.M., McKay D.M. Review article: helminths as therapeutic agents for inflammatory bowel disease. Aliment Pharmacol Ther 2004, 19(2):167-177.
45. Careaga M., Van de Water J., Ashwood P. Immune dysfunction in autism: a pathway to treatment. Neurotherapeutics 2010, 7(3):283-292.
46. Onore C., Careaga M., Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun 2012, 26(3):383-392.
47. Gupta S., Samra D., Agrawal S. Adaptive and innate immune responses in autism: rationale for therapeutic use of intravenous immunoglobulin. J Clin Immunol 2010, 30:S90-S96.
48. Siniscalco D., Sapone A., Giordano C., et al. The expression of caspases is enhanced in peripheral blood mononuclear cells of autism spectrum disorder patients. J Autism Dev Disord 2012, 42(7):1403-1410.
49. Ashwood P., Wills S., Van de Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol 2006, 80(1):1-15.
50. Wills S., Cabanlit M., Bennett J., Ashwood P., Amaral D., Van de Water J. Autoantibodies in autism spectrum disorders (ASD). Ann N Y Acad Sci 2007, 1107:79-91.
51. Goines P.E., Ashwood P. Cytokine dysregulation in autism spectrum disorders (ASD): Possible role of the environment. Neurotoxicol Teratol 2012, [pii: S0892-0362(12)00140-7].
52. Wolff M.J., Broadhurst M.J., Loke P. Helminthic therapy: improving mucosal barrier function. Trends Parasitol 2012, 28(5):187-194.
53. Theoharides T.C., Doyle R., Francis K., Conti P., Kalogeromitros D. Novel therapeutic targets for autism. Trends Pharmacol Sci 2008, 29(8):375-382.
54. de Theije C.G., Wu J., da Silva S.L., Kamphuis P.J., Garssen J., Korte S.M., et al. Pathways underlying the gut-to-brain connection in autism spectrum disorders as future targets for disease management. Eur J Pharmacol 2011, 668(Suppl. 1):S70-80.
55. Chen B., Girgis S., El-Matary W. Childhood autism and eosinophilic colitis. Digestion 2010, 81(2):127-129.
56. de Magistris L., Familiari V., Pascotto A., Sapone A., Frolli A., Iardino P., et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr 2010, 51(4):418-424.
57. Yap P., Fürst T., Müller I., Kriemler S., Utzinger J., Steinmann P. Determining soil-transmitted helminth infection status and physical fitness of school-aged children. J Vis Exp 2012, 66:e3966.
58. Flohr C., Quinnell R.J., Britton J. Do helminth parasites protect against atopy and allergic disease?. Clin Exp Allergy 2009, 39:20-32.
59. Elsabbagh M., Divan G., Koh Y.J., Kim Y.S., Kauchali S., Marcín C., et al. Global prevalence of autism and other pervasive developmental disorders. Autism Res 2012, 5(3):160-179.
60. Ying K.C., Browne G., Hutchinson M., Cashin A., Binh B.V. Autism in Vietnam: the case for the development and evaluation of an information book to be distributed at the time of diagnosis. Issues Ment Health Nurs 2012, 33(5):288-292.
61. http://www.ovamed.org.
62. Ferris J. For the good of the gut: can parasitic worms treat autoimmune diseases?. Sci Am 2010.
63. http://autoimmunetherapies.com/helminthic-therapy-worm-therapy-index.html.
64. Bager P., Kapel C., Roepstorff A., et al. Symptoms after ingestion of pig whipworm Trichuris suis eggs in a randomized placebo-controlled double-blind clinical trial. PLoS One 2011, 6(8):e22346.
65. Ashwood P., Anthony A., Pellicer A.A., Torrente F., Walker-Smith J.A., Wakefield A.J. Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J Clin Immunol 2003, 23(6):504-517.
66. Akuthota P., Weller P.F. Eosinophils and disease pathogenesis. Semin Hematol 2012, 49(2):113-119.
67. Bager P., Arnved J., Rønborg S., Wohlfahrt J., Poulsen L.K., Westergaard T., et al. Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol 2010, 125(1):123-130.
68. Klaver E.J., Kuijk L.M., Laan L.C., Kringel H., van Vliet S.J., Bouma G., et al. Trichuris suis-induced modulation of human dendritic cell function is glycan-mediated. Int J Parasitol 2013, 43(3-4):191-200.
69. http://www.clinicaltrials.gov.